In an innovative approach to colorectal cancer prevention and treatment,scientist are studying ways to replace missing metabolites in patients prone to gut inflammation and CRC. A new study in The American Journal of Pathology describes how administration of histamine-producing gut microbes to mice lacking the enzyme histidine decarboxylase (HDC) reduced inflammation and tumor formation.These results suggest that alteration of the gut microbiome with probiotics may become a new preventive or theraputic strategy for patients at risk for inflammatory bowel disease (IBD)-associated CRC.

“We are on the cusp of harnessing advances in microbiome science to facilitate diagnosis and treatment of human disease,”explains James Versalovic,MD,PhD,pathologist-in-chief at Texas Childrens Hospital,and Milton J. Finegold professor of pathology and immunology at Baylor College of Medicine(Houston).”By simply introducing mirobes that provide missing life substances,we can reduce the risk of cancer and supplement diet-based cancer prevention strategies.”

Source:Science Daily,